Analyst consensus available
Vrylar, jointly developed with US partner AbbVie, is the subject of the positive news
Several records were achieved last year, though
No one expected such a great performance
No new record in sales this quarter
Share price climbs to new all-time high
Jefferies publishes opinion
Vraylar sales skyrockets, revenue rises
Vraylar sequential growth to continue after lockdown
Target price, rating remain unchanged
First quarter turned out well, according to analysts
Management considered overly conservative
Revenue rose 28.2% y/y
Profit expected to jump from low base
Not just in the U.S. but in Europe as well
Mitsubishi Tanabe will distribute cariprazine in Thailand and Singapore.
With a 10% decrease in Russia and 20% in China
Revenue rose 8.5% to HUF 120 billion.
Analysts forecast 30% lower net profit.